Kohlberg & Company acquire Nelipak® Healthcare Packaging
CRANSTON, R.I., July 02, 2019 (GLOBE NEWSWIRE) -- Nelipak® Corporation, Inc. (“Nelipak”), the leading provider of custom designed rigid packaging for the medical device and pharmaceutical industries, announced today that it has been acquired by Kohlberg & Company, L.L.C. (Kohlberg), a private equity firm headquartered in Mount Kisco, NY., from Mason Wells. The business will continue to operate under the name of Nelipak® Healthcare Packaging.
Headquartered in Cranston, Rhode Island, Nelipak is the leading global manufacturer of custom-designed rigid healthcare packaging used for Class II and Class III medical devices, and pharma drug delivery products. The company operates strategically located cleanroom facilities meeting customers’ most stringent packaging requirements. Nelipaks’ experienced in-house design, development, prototyping, manufacturing and quality teams offer medical trays and blisters, surgical procedure trays, pharmaceutical handling trays, custom built sealing machines and other value-added services. With a staff of over 800, the company operates from seven production facilities, five in the Americas – located in Cranston, RI.; Whitehall, PA; Phoenix, AZ.; Humacao, Puerto Rico, San Jose, Costa Rica; two in Europe - located in Venray, the Netherlands and Galway, Ireland.
“We have accomplished a lot at Nelipak during the past six years, and we are very grateful for the support given to us by Mason Wells. Our future is very bright with Kohlberg,” said Mike Kelly, President and CEO of Nelipak. “Kohlberg is committed to investing in Nelipak to make us an even stronger organization with additional capabilities to offer our customers around the world. With our global locations, world class design team, modern cleanroom manufacturing, strong sales organization and experienced management team, Nelipak is well positioned to take advantage of growth opportunities in the market.”
“Nelipak has successfully transformed itself into a leading global player in healthcare packaging and an ideal platform for further industry consolidation,” commented Seth H. Hollander, Partner of Kohlberg. “Our plans include leveraging Mike and his team, and their customer relationships, with sizeable, global acquisitions.” Roger Prevot, Operating Partner of Kohlberg, added, “A business with Nelipak’s global market position represents a unique investment opportunity. We look forward to supporting Mike and his team as they continue to execute their plan for organic and M&A-driven growth, while continuing to provide their customers with best-in-class service.”
About Nelipak® Healthcare Packaging
With facilities in Cranston, RI; Whitehall, PA; Phoenix, AZ; Venray, the Netherlands; Galway, Ireland; Humacao, Puerto Rico; and San Jose, Costa Rica, Nelipak® Healthcare Packaging designs, develops and manufactures custom thermoformed packaging products that provide superior protection for medical devices and pharmaceuticals. The company offers medical trays and blisters, surgical procedure trays, pharmaceutical handling trays, custom built sealing machines and other value-added services. Nelipak® Healthcare Packaging customers consist of some of the largest and most reputable medical device and pharmaceutical companies in the world. With over 800 employees worldwide, Nelipak® is focused on delivering superior quality and customer experience through world class manufacturing at each of its locations.
Nelipak® Healthcare Packaging is a trade name of Nelipak Corporation
About Kohlberg & Company, LLC
Kohlberg & Company, LLC (“Kohlberg”) is a leading private equity firm headquartered in Mount Kisco, New York. Since its inception in 1987, Kohlberg has organized eight private equity funds, through which it has raised over $7.5 billion of committed equity capital. Over its 32-year history, Kohlberg has completed 76 platform investments and nearly 200 add-on acquisitions, with an aggregate transaction value in excess of $15 billion. For more information, please visit www.kohlberg.com.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
FRO - Invitation to Q3 2019 Results Conference Call and Webcast19.11.2019 13:16:00 CET | Press release
Frontline Ltd.’s preliminary third quarter 2019 results will be released on Wednesday November 27 2019, and a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section at www.frontline.bm ahead of the conference call. In order to attend the conference call you may do one of the following: a. Webcast Go to the Investor Relations section at www.frontline.bm and follow the “Webcast” link. b. Conference Call Participant dial-in telephone numbers: Norway +47 2156 3162 Norway toll free 800 10392 UK +44 (0) 203 009 5710 UK Toll Free 0 800 376 7425 USA +1 917 720 0178 USA Toll Free 866 869 2321 Conference ID 5598374 Participants will be asked for their full name & Conference ID. A Q&A session will be held after the teleconference/webcast. Information on how to submit questions will be given at the beginning of the session. The presentation material which will be used in th
Oasmia offentliggör prospekt i samband med företrädesemission om cirka 399 MSEK samt uppdaterad information som återfinns i prospektet19.11.2019 13:00:00 CET | Pressemelding
EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE SKULLE VARA I STRID MED GÄLLANDE REGLER ELLER KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER ÄN VAD SOM FÖLJER AV SVENSK RÄTT. Styrelsen i Oasmia Pharmaceutical AB (“Oasmia” eller ”Bolaget”) meddelande den 11 november 2019 om genomförandet av en nyemission av aktier med företrädesrätt för Oasmias befintliga aktieägare om cirka 399 MSEK ("Företrädesemissionen"). Bolaget har med anledning av Företrädesemissionen upprättat ett prospekt som idag godkänts och registrerats av Finansinspektionen. Offentliggörande av prospekt För fullständig information om Företrädesemissionen hänvisas till det prospekt som upprättats av Bolaget samt idag godkänts och registrerats av Finansinspektionen per dagens datum.
Oasmia publishes prospectus in connection with the rights issue of approximately SEK 399 million and updated information included in the prospectus19.11.2019 13:00:00 CET | Press release
Not for release, publication or distribution, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, South Africa, Switzerland, Singapore, the United States or any other jurisdiction where such distribution of this press release would be subject to legal restrictions. This press release does not constitute an offer of any securities of Oasmia Pharmaceuticals AB (publ). See the section “IMPORTANT INFORMATION” below. The board of Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) announced on 11 November 2019 to carry out a new issue of shares with preferential rights for Oasmia’s shareholders of approximately SEK 399 million (the “Rights Issue”). As a result of the Rights Issue, the Company has prepared a prospectus, which has been approved and registered by the Swedish Financial Supervisory Authority today. Publication of the prospectus For complete information on the Rights Issue, refer to the prospectus that has been prepared by Oasmia as well as appro
Medtronic Reports Second Quarter Financial Results19.11.2019 12:45:00 CET | Press release
Revenue of $7.7 Billion Increased 3.0% Reported and 4.1% Organic GAAP Diluted EPS of $1.01; Non-GAAP Diluted EPS of $1.31 Cash Flow from Operations of $1.9 Billion Grew 61%; Free Cash Flow of $1.6 Billion Grew 66% Company Raises FY20 EPS Guidance DUBLIN, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2020, which ended October 25, 2019. The company reported second quarter worldwide revenue of $7.706 billion, an increase of 3.0 percent as reported or 4.1 percent on an organic basis, which adjusts for a $97 million negative impact from foreign currency and a $16 million contribution from the company’s acquisition of Titan Spine, which is reported in the Spine division in the Restorative Therapies Group. As reported, second quarter GAAP net income and diluted earnings per share (EPS) were $1.364 billion and $1.01, respectively. As detailed in the financial schedules included through the link at the end of t
Avenir LNG collaborates with Golar Power on developing small-scale LNG distribution in Brazil19.11.2019 12:00:00 CET | Press release
London, Nov. 19, 2019 (GLOBE NEWSWIRE) -- Avenir LNG Limited (“Avenir”) wishes to announce that it will collaborate with Golar Power Limited (“Golar Power”) in developing the small-scale LNG market in Brazil. Avenir’s second 7,500 cbm LNG Carrier will be used to deliver LNG to various ports across Brazil upon delivery. The vessel will also offer ship-to-ship bunkering capability as part of Avenir’s global multi-nodal bunkering solution; adding to the Colombian, Mediterranean and Malaysian nodes which the company currently offers. Commenting on the collaboration with Golar Power, Andrew Pickering, Chief Executive Officer of Avenir LNG Limited, said, “This is another step in our strategy where we are working closely with a shareholder in leveraging its FSRU platform to develop small-scale LNG distribution and bunkering in key developing markets.” Commenting on the collaboration with Avenir LNG, Eduardo Antonello, Chief Executive Officer of Golar Power Limited, said, “Accessing small-scal
Conversion factor for Exchange offer in SGB IL 3102 2019-11-1919.11.2019 11:03:00 CET | Press release
2019-11-19 Conversion factor SGB IL 3102/3109; 0.8381954 The conversion factor of SGB IL 3102/3109 indicates the amount of SGB IL 3102 that the SNDO will buy back for each SGB IL 3109 issued in the switch auction at November 19, 2019. For further information, please contact: The funding desk + 46 8 613 4780 Funding@riksgalden.se